Orla Hardiman BSc MD FRCPI FTCD MRIA Professor of Neurology Trinity College Dublin
|
|
- Blaise Bradley
- 5 years ago
- Views:
Transcription
1 Orla Hardiman BSc MD FRCPI FTCD MRIA Professor of Neurology Trinity College Dublin
2 ALS IS A HUMAN DISEASE
3 ALS: A Gene-environment Interaction (in 6 steps) 3-5 additional events Hardiman & Al-Chalabi Nat Rev Neurol 2013 Al-Chalabi et al Lancet Neurol 2015
4 FINDING THE GENES
5 ALS IS A SYNDROME: SUBCOHORTS CAN BE IDENTIFIED BASED ON CLINICAL PHENOTYPING & GENOMICS
6 ALS TRIALS > 40 negative trials Animal-based approach has not been successful Effective treatments likely to be in subgroups of patients Better biomarkers required Trial design and outcome measures need to be refined
7 EVENTUALLY, ALS WILL BE SEGREGATED BY SPECIFIC CHARACTERISTICS
8 IMPLICATIONS FOR FUTURE CLINICAL TRIALS
9 Over 20 compounds now in late pre-clinical phase
10 CLINICAL TRIALS (Currently Recruiting) 24 Phase 2 Trials 4 Phase 3 Trials
11 PRECISION MEDICINE Precision Medicine refers to the tailoring of medical treatment to the individual characteristics of each patient..it relates to the ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease, in the biology and/or prognosis of those diseases they may develop, or in their response to a specific treatment.
12 Treatment Research Initiative to Cure ALS
13 MISSION THE RIGHT DRUG, FOR THE RIGHT PATIENT, IN THE RIGHT DOSE, AT THE RIGHT TIME
14 OBJECTIVES
15 BETTER PATIENT SELECTION
16 DISEASE PROGRESSION IS HETEROGENEOUS Human ALS Patients VARIATONS IN RATE OF CLINICAL DECLINE
17 ALS PROGRESSION: PREDICTIVE FACTORS Age of onset Cognitive & behavioural status Site of onset Rate of progression Genetic background
18 Hierarchical Clustering identifies 3 groups Elamin et al J Neurol 2015
19 30 GENES OF MAJOR EFFECT
20 BETTER PATIENT SELECTION
21 BETTER BIOBANKING Lymphocytes Fibroblasts ips cells Brain & spinal cord
22 RECOGNITION OF EXTRA- MOTOR COMPONENTS
23 COGNITIVE & BEHAVIOURAL SUBPHENOTYPES
24 BETTER MEASURES OF PROGRESSION
25 ALSFRS-R Vital Capacity
26 Graph of longitudinal total ALSFRS-R and ALSFRS-R subscores. James Rooney et al. J Neurol Neurosurg Psychiatry 2017;88: by BMJ Publishing Group Ltd
27 BETTER BIOMARKERS INCLUDING MARKERS OF COGNITIVE AND BEHAVIOURAL CHANGE
28 BETTER NEUROIMAGING CAN NOW RELIABLY DISTINGUISH ANATOMIC REGIONS OF INVOLVEMENT
29
30 NEW NEUROPHYSIOLOGIC MEASURES
31 !
32 HARNESSING SOURCE LOCALISATION TECHNOLOGY Source-localisation Sensor-space Source-space
33 Results: Using eloreta Provides activity for sources throughout the brain, low resolution 10*log 10 (Deviant power / Standard power) Top 75% of differences between ALS and Patients
34 BETTER LABORATORY BIOMARKERS Neurofilament light & Heavy Chain Other blood biomarkers serum folate uric acid, L-ferritin Chitotriosidase, NOX2 enzyme activity, LDL/HDL ratio, creatine kinase, creatinine, albumin, vitamin D Neuroinflammatory markers MicroRNAs
35 BETTER DATA COLLECTION
36 REALTIME DATA UPLOADS for TRIAL READINESS A pan-european Electronic Patient Record
37 PRECISION MEDICINE Precision Medicine refers to the tailoring of medical treatment to the individual characteristics of each patient..it relates to the ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease, in the biology and/or prognosis of those diseases they may develop, or in their response to a specific treatment.
38 NEW DESIGNER TREATMENTS Based on genetics Anti-sense oligonucleotides SOD1 C9orf72 repeat expansion Based on pharmacogenomics
39 EARLY WINS: 3 NEW INVESTIGATOR-LED TRIALS LIGHTHOUSE 2 Triumeq targeting HERVK in ALS ADORE Oral Edaravone PRELUDE UNC13Allele determines response to Lithium therapy
40 LIGHTHOUSE II 10% of the human genome encodes for endogenous retroviruses (HERVs) HERV-K is the most recent HERV to be integrated into the human genome. Reverse transcriptase elevated in motor neurons from some patients with ALS
41 LIGHTHOUSE II Triumeq (an HIV antiretroviral drug) inhibits HERV-K A Phase IIa open-label, safety and tolerability trial of Triumeq was conducted in 40 patients with ALS Triumeq is safe and showed a strong potential for biological activity. Phase 3 double blind trial scheduled in Europe, Australia & US with better enrolment and outcomes
42 ADORE Oxidative stress markers are higher in patients with ALS and may relate to disease progression. Edaravone is a free-radical scavenger that has been shown to inhibit motor neuron death by reducing oxidative stress. Licensed by FDA in IV formulation for ALS (but not by the EMEA)
43 ADORE Oral formulation may improve the effectiveness of Edaravone by a more constant exposure. Better recruitment Better outcome measures
44 NEW DESIGNER TREATMENTS Based on genetics Anti-sense oligonucleotides SOD1 C9orf72 repeat expansion Based on pharmacogenomics
45 PHARMACOGENOMICS PRELUDE: Investigator initiated trial Safety and efficacy of lithium carbonate in patients with ALS and UNC13A C-allele homozygosity
46 PRELUDE
47
48 EVENTUALLY, ALS WILL BE SEGREGATED BY SPECIFIC CHARACTERISTICS
49 WHAT IT WILL LOOK LIKE
50 CONCLUSIONS New treatments in ALS will be driven by a precision medicine approach Better patient selection, trial design and improved outcome measures will move the field forward
51 Clinical Bernie Corr Sara Colla Dr.Deirdre Murray Lesley Doyle Kitty McElligott Imaging & EEG Dr.Peter Bede Dr.Bahman Nasseroleslami Dr.Parames Iyer Dr.Eoghan Finnegan Dr.Amina Coffey Dr.Christina Schuster Stefan Dukic Roisin McMackin Team Neuropsychology Dr.Niall Pender Dr.Tom Burke Marta Pinto Epidemiology Dr.Marie Ryan Dr. James Rooney Mark Heverin (Register) Dr.Katy Tobin Genetics Prof Dan Bradley Dr.Russell McLaughlin Dr. Kevin Kenna Ross Byrne Mark Doherty Academic Neurology Dominique Plant Health Services Dr. Miriam Galvin Dr.Katy Tobin Dr.Sinead Maguire EMG & Biomarkers Dr.Taha Omar Dr.Amina Coffey Clinical Trials Liz Fogarty Research Manager Mark Heverin Laboratory/Neuropharm Dr. Julie Kelly Gill Slator
52 RESEARCH FUNDING
PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS
PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS BACKGROUND Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND) is
More informationYoung Onset Neurodegeneration study
Young Onset Neurodegeneration study Neurology at the Memory Clinic Dr Thomas Monaghan SpR in Neurology Memory, Cognitive Studies and Behavioral Neurology Clinics at St James s Dr Colin Doherty / Prof Brian
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/14/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RADICAVA (edaravone) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationNeurodegenerative Disorders
Neurodegenerative Disorders Orla Hardiman Colin P. Doherty Editors Marwa Elamin Peter Bede Associate Editors Neurodegenerative Disorders A Clinical Guide Second Edition Editors Orla Hardiman Academic
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Amyotrophic Lateral Sclerosis 10 (ALS10) and Amyotrophic Lateral Sclerosis 6 (ALS6)
More informationRadicava (edaravone)
*- Florida Healthy Kids Radicava (edaravone) Override(s) Prior Authorization Approval Duration 1 year Medications Radicava (edaravone) APPROVAL CRITERIA Requests for Radicava (edaravone) may be approved
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Radicava GENERIC NAME edaravone MANUFACTURER MT Pharma America, Inc. DATE OF APPROVAL May 5, 2017 PRODUCT LAUNCH DATE May 5, 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationPREDICT-HD. PREDICT-HD: Paving the Way Toward Clinical Trials. Dr. Jane Paulsen Principal Investigator PREDICT-HD
: Paving the Way Toward Clinical Trials Dr. Jane Paulsen Principal Investigator Professor of Neurology, Psychiatry, Psychology and Neuroscience University of Iowa Carver College of Medicine Disclosures
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
28 January 2016 EMA/CHMP/131550/2015 Committee for Human Medicinal Products (CHMP) Overview of comments received on ' Guideline on clinical investigation of medicinal products for the treatment of amyotrophic
More informationGenetic testing in ALS A survey of current practices
VIEWS & REVIEWS Published Ahead of Print on February 3, 2017 as 10.1212/WNL.0000000000003686 Genetic testing in ALS A survey of current practices Alice Vajda, PhD Russell L. McLaughlin, PhD Mark Heverin,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Radicava) Reference Number: CP.PHAR.343 Effective Date: 07.01.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Coding Implications Revision Log See
More informationSEMINAR PROGRAMME Join us on Twitter #brainpower
SEMINAR PROGRAMME Join us on Twitter #brainpower Seminar Programme 09:30 Registration and refreshments 10:00 Introduction and welcome Barbara O Connell Chief Executive Session 1: Current trends in evidence
More informationEach plenary presentation is 25 minutes plus 5 minutes questions; each platform presentation is 12 minutes plus 3 minutes for questions.
ENCALS DRAFT PROGRAM Oxford 20 th -22 nd June 2018 Each plenary presentation is 25 minutes plus 5 minutes questions; each platform presentation is 12 minutes plus 3 minutes for questions. WEDNESDAY 20
More informationSupport for the Road Ahead
Every ALS Journey Is Different Understanding Your Options Is the First Step Forward Helpful Information for Those Newly Diagnosed with ALS Support for the Road Ahead Receiving a diagnosis of ALS can be
More informationMentis Cura November
Mentis Cura November 29 2012 www.mentiscura.com New Facts on Alzheimer s Death rank nr. 2-5 in western countries Fastest growing disease in: Cost Incedence Death rate People with Alzheimer s 2012 36 million
More informationAEVI-001: SAGA Trial in mglur+ ADHD
AEVI-001: SAGA Trial in mglur+ ADHD Topline Results March 20, 2017 2017, Aevi Genomic Medicine Forward-Looking Statement This presentation includes certain estimates and other forward-looking statements
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationSurvival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics
Schuster et al. BMC Neurology (2017) 17:73 DOI 10.1186/s12883-017-0854-x RESEARCH ARTICLE Open Access prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics Christina
More informationIs ALS a multistep process?
Is ALS a multistep process? Neil Pearce, London School of Hygiene and Tropical Medicine Ammar Al-Chalabi, Institute of Psychiatry, King s College London Zoe Rutter-Locher, King s College London Is ALS
More informationClinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327
Clinical Policy: (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNorth Dublin Hospital Group
Research and Education Conference Programme North Dublin Hospital Group Inaugural Conference on Collaborative Lifespan Research Thursday 29th November 2012 The Pillar Room, The Rotunda Hospital Research
More informationReach2HD Phase 2 Clinical Trial Top Line Results. Investor Conference Call 19 th February 2014
Reach2HD Phase 2 Clinical Trial Top Line Results Investor Conference Call 19 th February 2014 Safe Harbour This presentation may contain some statements that may be considered Forward-Looking Statements,
More informationClinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.
UvA-DARE (Digital Academic Repository) Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. Link to publication Citation for published version (APA): Post, B. (2009). Clinimetrics,
More informationRe: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities
Public Policy Division 202.393.7737 p 1212 New York Ave NW 866.865.0270 f Suite 800 www.alz.org Washington, DC 20005 Roderick Corriveau, Ph.D. Program Director National Institute of Neurological Disorders
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Edaravone Table of Contents Coverage Policy... 1 FDA Approved Indications... 2 General Background... 2 Coding/Billing Information... 5 References... 5 Effective
More informationAmyotrophic lateral sclerosis causes small fiber pathology
SHORT COMMUNICATION Amyotrophic lateral sclerosis causes small fiber pathology E. Dalla Bella a,b, R. Lombardi b, C. Porretta-Serapiglia b, C. Ciano a,c, C. Gellera a,d, V. Pensato a,d, D. Cazzato b and
More informationMOTOR FUNCTION AND BEHAVIOUR ACROSS THE ALS-FTD SPECTRUM
MOTOR FUNCTION AND BEHAVIOUR ACROSS THE ALS-FTD SPECTRUM Dinuksha De Silva, 1, 2 Sharpley Hsieh 4, Jashelle Caga, 4 Felicity V.C. Leslie, 1,2,3 Matthew C. Kiernan, 1, 4 John R. Hodges, 1, 2, 3 Eneida Mioshi,
More informationFamilial ALS 101. Michael Benatar. ALS Advocacy Day May 13-15, 2012 Washington DC
Familial ALS 101 Michael Benatar ALS Advocacy Day May 13-15, 2012 Washington DC Questions about familial ALS What is fals? What causes fals? How common? Registries? Twin studies? Which genes? Genetic Testing?
More informationNutrition and the Ageing Brain: can specific foods and nutrients help to preserve better cognition in older adults?
Nutrition and the Ageing Brain: can specific foods and nutrients help to preserve better cognition in older adults? Helene McNulty PhD RD MRIA Director of the Nutrition Innovation Centre for Food and Health
More information13:45-14:15 Dr. Janez Faganel Memorial Lecture: Prof. Jernej Ule (London, UK) "Protein-RNA complexes & ALS: insights from iclip"
Programme ENCALS Meeting Ljubljana 2017 18-20 May 2017 Cankarjev dom Cultural and Congress Centre Ljubljana, Slovenia Thursday, 18 May 12:00-13:30 Registration and lunch / Second Foyer 13:30-13:45 Opening
More informationHealing After Plague: Lessons Applied. Emerging Concepts
Healing After Plague: Lessons Applied Emerging Concepts Recombination events in animal and human cells can generate families of infectious related gamma retroviruses Greatest concern is that they have
More informationAmyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry
Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationThe new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers
The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers A. Petzold M.J. Eikelenboom G. Keir C.H. Polman B.M.J. Uitdehaag E.J. Thompson G. Giovannoni 04.08.2005
More informationNeuroimaging and Neurostimulation: Going inside the black box
Neuroimaging and Neurostimulation: Going inside the black box Benzi M. Kluger M.D., M.S. Director, Movement Disorders Center Associate Professor of Neurology & Psychiatry University of Colorado OUTLINE
More informationmetabolism Kirk Hogan M.D., J.D.
Nitrous oxide (N 2 O) toxicity and cobalamin (B 12 )-dependent metabolism Kirk Hogan M.D., J.D. Department of Anesthesiology, University of Wisconsin Madison APSF Stoelting Conference
More informationHuntington s Disease. An Update on Latest Research. HD Center of Excellence
Huntington s Disease An Update on Latest Research HD Treatment gcurrent treatments are symptomatic. gseveral compounds have delayed onset and slowed progression in mouse models. gquestion remains to translate
More informationOriginal Science. Evaluation of Multiple Standard Laboratory Parameters in Amyotrophic Lateral Sclerosis
Evaluation of Multiple Standard Laboratory Parameters in Amyotrophic Lateral Sclerosis Bandhu Paudyal, MBBS 1 ; Nabil Ahmad, MD 1 ; James B. Caress, MD 1 ; Leah P. Griffin, MS 2 ; and Michael S. Cartwright,
More informationDepression: An Important Risk Factor for Cognitive Decline
Depression: An Important Risk Factor for Cognitive Decline No conflicts of interest Sarah K. Tighe, M.D. Assistant Professor University of Iowa Carver College of Medicine Department of Psychiatry Institute
More informationIoana Agache Transylvania University Brasov. Precision medicine in allergy and asthma
Ioana Agache Transylvania University Brasov Precision medicine in allergy and asthma Precision medicine and precision health Personalized care based on molecular, immunologic and functional endotyping
More informationPrecision Health Economics, Not Just Genetics
Precision Health Economics, Not Just Genetics The Impact of Real-World User Behavior and Treatment Adherence Patterns on Health and Economic Outcomes Janne Martikainen Professor (pharmacoeconomics) Deputy
More informationCOGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E
COGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E Attention Problem Solving Language Cognitive Domains Decision Making Memory Reasoning The Cardiovascular Health Cognition Study shows higher S
More informationNeuroimaging biomarkers and predictors of motor recovery: implications for PTs
Neuroimaging biomarkers and predictors of motor recovery: implications for PTs 2018 Combined Sections Meeting of the American Physical Therapy Association New Orleans, LA February 21-24, 2018 Presenters:
More informationGenetics And Neural Plasticity After Stroke
Genetics And Neural Plasticity After Stroke Steven C. Cramer, MD Professor, Depts. Neurology, Anatomy & Neurobiology, and PM&R Clinical Director, Sue & Bill Gross Stem Cell Research Center Associate Director,
More informationMSc In Translational Neuroscience.
Faculty Of Medicine Dentistry & Health. Faculty Of Science. MSc In Translational Neuroscience. www.sheffield.ac.uk/transneuro MSc in Translational Neuroscience. Why translational neuroscience? Translational
More informationPro-Oxidant Environmental Exposures: Implications of Redox Imbalance in Autism S. Jill James, Ph.D.
Pro-Oxidant Environmental Exposures: Implications of Redox Imbalance in Autism S. Jill James, Ph.D. Professor, Department of Pediatrics Director, Autism Metabolic Genomics Laboratory Arkansas Children
More informationTheme Topics Subtopics. Basic and Translational Science. Development of New Models and Analysis Methods
Basic and Translational Science Development of New Models and Analysis Methods α-synuclein Amyloid/Abeta Behavioral models Inflammation Novel assays and technologies Screening studies/platforms Seeding
More informationMeasuring network disruption in neurodegenerative diseases: New approaches using signal analysis
1 Academic Unit of Neurology, Trinity College Dublin, the University of Dublin, Dublin, Ireland 2 Department of Neurology, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany 3
More informationNext generation therapeutics and personalised care for Epilepsy
RCSI Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn Next generation therapeutics and personalised care for Epilepsy Professor David C. Henshall, Ph.D. Department of Physiology
More informationServier and GeNeuro Announce Promising post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017
Servier and GeNeuro Announce Promising post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017 Anti-inflammatory effect observed in post hoc analysis in active population at 24
More informationToward a more accurate delimitation of the epileptic focus from a surgical perspective
Toward a more accurate delimitation of the epileptic focus from a surgical perspective Margitta Seeck Department of Clinical Neurosciences EEG & Epilepsy Unit University Hospital of Geneva Geneva, Switzerland
More informationFor more information about any of these trials, please contact the listed study coordinator or one of our research nurses:
Inosine Researchers are currently enrolling people with ALS in a research study which is evaluating the safety of Inosine, a supplement that is used to raise blood levels of uric acid. Your participation
More informationErasmus & Visiting Students: Modules & Assessments
School of Psychology Erasmus & Visiting Students: Modules & Assessments 2018 2019 PLEASE NOTE: These modules are currently provisional and subject to change before the start of the academic year. Please
More informationAmyotrophic lateral sclerosis (ALS) is characterized by
REVIEW Quantifying Disease Progression in Amyotrophic Lateral Sclerosis Neil G. Simon, MBBS, 1,2,3 Martin R. Turner, PhD, 4 Steve Vucic, PhD, 3,5 Ammar Al-Chalabi, PhD, 6 Jeremy Shefner, MD, PhD, 7 Catherine
More informationTest & Treat : Changing the face of insurance for persons living with HIV?
Test & Treat : Changing the face of insurance for persons living with HIV? Kadene Gibbs FSA, MSc Dr Matthew Procter Agenda 1. Background 2. Understanding HIV and Factors affecting Prognosis 3. History
More information7/20/17. Objectives. Genetic variation in candidate biomarkers predicts recovery and may affect biomarker utility. Nicole Osier, PhD, RN
Genetic variation in candidate biomarkers predicts recovery and may affect biomarker utility Nicole Osier, PhD, RN TBI* Objectives Describe the state-of-the-science for traumatic brain injury as it relates
More informationA progress report on the Joint Programming Initiative
A progress report on the Joint Programming Initiative In April 2010, Alzheimer Europe talked about the aims of the Joint Programming Initiative on Neurodegenerative Diseases (JPND) with the Initiative
More informationLecture 1: Introduction to Personalized Medicine. Donglin Zeng, Department of Biostatistics, University of North Carolina
Lecture 1: Introduction to Personalized Medicine Personalized Medicine A Quick View Personalized Medicine is a general medical paradigm referring to systematic use of individual patient information to
More informationCongenital Heart Disease and Critical Neurological Injury: Do Our Patients Belong in a Neurocritical Care Unit?
Congenital Heart Disease and Critical Neurological Injury: Do Our Patients Belong in a Neurocritical Care Unit? Shriprasad R Deshpande, MBBS MS Assistant Professor of Pediatrics Medical Director, Mechanical
More informationThe century of the system
The century of the system Integrated collaborative care for depression in patients with cancer Michael Sharpe Professor of Psychological Medicine Points The importance of systems of care Epidemiology of
More informationNeuroscience 410 Huntington Disease - Clinical. March 18, 2008
Neuroscience 410 March 20, 2007 W. R. Wayne Martin, MD, FRCPC Division of Neurology University of Alberta inherited neurodegenerative disorder autosomal dominant 100% penetrance age of onset: 35-45 yr
More informationCurrent and near-term impact of biomarkers for multiple sclerosis Gavin Giovannoni
Current and near-term impact of biomarkers for multiple sclerosis Gavin Giovannoni Institute of Cell and Molecular Science Queen Mary's School of Medicine and Dentistry Barts and The London NHS Trust The
More informationUsing Biomarkers to Increase the Efficiency of Early Stage Drug Development
Using Biomarkers to Increase the Efficiency of Early Stage Drug Development Personal consulting compensation received from Cytokinetics, Biogen, MT Pharma, Lilly, Karyopharm, Denali Goals of Talk Describe
More informationSpinal Muscular Atrophy as a Focus Indication for Biomarker Development. Meg Winberg, PhD Spinal Muscular Atrophy Foundation February 26, 2007
Spinal Muscular Atrophy as a Focus Indication for Biomarker Development Meg Winberg, PhD Spinal Muscular Atrophy Foundation February 26, 2007 Why SMA? p Low incidence, but a large orphan indication p Scientifically
More informationArticles. Copyright The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study Ton Fang, Ahmad Al Khleifat, Jacques-Henri
More informationTon Fang, Ahmad Al Khleifat, Jacques-Henri Meurgey, Ashley Jones, P Nigel Leigh, Gilbert Bensimon, Ammar Al-Chalabi
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study Ton Fang, Ahmad Al Khleifat, Jacques-Henri
More informationNew lexicon and criteria for the diagnosis of Alzheimer's disease
Edith Cowan University Research Online ECU Publications Pre. 2011 2011 New lexicon and criteria for the diagnosis of Alzheimer's disease Hamid Sohrabi Edith Cowan University Michael Weinborn Johanna Badcock
More informationSMA IS A SEVERE NEUROLOGICAL DISORDER [1]
SMA OVERVIEW SMA IS A SEVERE NEUROLOGICAL DISORDER [1] Autosomal recessive genetic inheritance 1 in 50 people (approximately 6 million Americans) are carriers [2] 1 in 6,000 to 1 in 10,000 children born
More informationENTRY INTO AND RETENTION IN CARE AND MONITORING ANTIRETROVIRAL ADHERENCE FOR PERSONS WITH HIV
ENTRY INTO AND RETENTION IN CARE AND MONITORING ANTIRETROVIRAL ADHERENCE FOR PERSONS WITH HIV Michael J. Mugavero, MD, MHSc University of Alabama at Birmingham Guidelines Developed by a Panel Convened
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationTOXIC AND NUTRITIONAL DISORDER MODULE
TOXIC AND NUTRITIONAL DISORDER MODULE Objectives: For each of the following entities the student should be able to: 1. Describe the etiology/pathogenesis and/or pathophysiology, gross and microscopic morphology
More informationWebinar recording/presentation
Webinar recording/presentation Perth, Australia & Malta 12 July 2018 Neurotech International Limited (ASX:NTI) ( Neurotech or the Company ), developer of quality medical solutions improving the lives of
More informationCHANGES AT A GLANCE. WHAT S NEW AND DIFFERENT? SEPTEMBER 2017.
CHANGES AT A GLANCE. WHAT S NEW AND DIFFERENT? SEPTEMBER 2017. Enhancements to CommInsure Protection: Income Protection more IP cover options to suit your circumstances Introducing Income Care Platinum,
More informationEast Meets West Medicine Forum
East Meets West Medicine Forum Jerome Sarris Professor of Integrative Mental Health Deputy Director, NICM, Western Sydney University; NHMRC Clinical Research Fellow; Honorary Principal Research Fellow,
More informationThe Contribution of TMS-EEG Coregistration in the Exploration of the Human Connectome
IRCCS San Giovanni di Dio Fatebenefratelli The Contribution of TMS-EEG Coregistration in the Exploration of the Human Connectome Marta Bortoletto Carlo Miniussi Cognitive Neuroscience Section, The Saint
More informationFREQUENTLY ASKED QUESTIONS ABOUT RADICAVA (EDARAVONE)
FREQUENTLY ASKED QUESTIONS ABOUT RADICAVA (EDARAVONE) What is RADICAVA? RADICAVA (edaravone) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) to treat people with amyotrophic
More informationRESEARCH CAPACITY DEVELOPMENT INITIATIVE (RCDI)
RESEARCH CAPACITY DEVELOPMENT INITIATIVE (RCDI) BACKGROUND TO THE INITIATIVE The South African Medical Research Council (SAMRC,) in driving biomedical research and aiming to build a healthy nation through
More informationEuropean Commission Grants Approval for Mavenclad (Cladribine Tablets)
Your Contact Friederike Segeberg +49 6151 72-6328 Investor Relations +49 6151 72-3321 August 25, 2017 European Commission Grants Approval for Mavenclad (Cladribine Tablets) First oral short-course treatment
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationAutoimmune encephalopathieslatest. Prof Belinda Lennox Department of Psychiatry, University of Oxford
Autoimmune encephalopathieslatest advances Prof Belinda Lennox Department of Psychiatry, University of Oxford Belinda.lennox@psych.ox.ac.uk RCP Advanced Medicine 20 th June 2016 Declarations of Interest
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationHIV Neurology Persistence of Cognitive Impairment Despite cart
HIV Neurology Persistence of Cognitive Impairment Despite cart Victor Valcour MD PhD Professor of Medicine Memory and Aging Center, Dept. of Neurology University of California San Francisco, USA 8 th International
More informationHuman Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS
Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s
More informationBasket and Umbrella Trial Designs in Oncology
Basket and Umbrella Trial Designs in Oncology Eric Polley Biomedical Statistics and Informatics Mayo Clinic Polley.Eric@mayo.edu Dose Selection for Cancer Treatment Drugs Stanford Medicine May 2017 1 /
More informationWhat are the Latest Treatment Advances in Parkinson disease
What are the Latest Treatment Advances in Parkinson disease Fatta B. Nahab, M.D. Associate Professor of Neurosciences Director, Functional Imaging of Neurodegenerative Disorders Lab Overview Recently approved
More informationPrevalence, type and factors associated with HPV infection at multiple sites in young HIV- positive MSM
Prevalence, type and factors associated with HPV infection at multiple sites in young HIV- positive MSM On behalf of the HPV MAPS Research Group C Sadlier 1,2, S O Dea 1, S Delamere 1, P Smyth 3, N Myers
More informationUniversity Health Network Scholarly List
University Health Network Scholarly List TORONTO GENERAL HOSPITAL Lorenzo Del Sorbo Lorenzo.Delsorbo@uhn.ca IDCCM Staff Job Description: Clinician Investigator 1. Basic science 2. Physiologic studies 1.
More informationHand of Hope. For hand rehabilitation. Member of Vincent Medical Holdings Limited
Hand of Hope For hand rehabilitation Member of Vincent Medical Holdings Limited Over 17 Million people worldwide suffer a stroke each year A stroke is the largest cause of a disability with half of all
More informationClinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationTowards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco
Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or
More informationSelecting and interpreting markers of immunomodulation in nutrition studies. Jalil Benyacoub, PhD Nutrition & Immunity task force
Selecting and interpreting markers of immunomodulation in nutrition studies Jalil Benyacoub, PhD Nutrition & Immunity task force Outlines Overview on the immune system, immune functions and Nutrition Summary
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationEvolution of Early Phase Trials: Clinical Trial Design in the Modern Era
Evolution of Early Phase Trials: Clinical Trial Design in the Modern Era Shivaani Kummar, MD, FACP Professor of Medicine (Oncology) Director, Phase I Clinical Research Program Co-Director, Translational
More informationDiscovery & Validation of Kidney Injury Biomarkers
Dublin Academic Medical Centre Discovery & Validation of Kidney Injury Biomarkers Patrick Murray, MD, FASN, FRCPI, FJFICMI Professor, University College Dublin, Mater Misericordiae University Hospital,
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More informationToward the Safe Use of Lentivirus and Retrovirus Vector Systems
27 July, 2017 The Asian Conference on Safety & Education in Laboratory Toward the Safe Use of Lentivirus and Retrovirus Vector Systems Takaomi Sanda, MD, PhD Principal Investigator, Cancer Science Institute
More informationCONSULTATION / LIAISON PSYCHIATRY
CONSULTATION / LIAISON PSYCHIATRY Dr. Jon Hunter, MD Tel: 416-586-4800 ext. 4557 Fax: 416-586-5970 Email: jhunter@mtsinai.on.ca Jeanette Villapando Tel: 416-586-4800 ext. 8493 Fax: 416-586-8654 Email:
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information